- Home
- CEV vs CLNN Comparison
CEV vs CLNN Comparison
Compare CEV & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEV | CLNN |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.9M | 67.5M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CEV | CLNN |
|---|---|---|
| Price | $10.65 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $33.75 |
| AVG Volume (30 Days) | 26.5K | ★ 77.6K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $200,000.00 |
| Revenue This Year | N/A | $17.64 |
| Revenue Next Year | N/A | $19,516.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.40 | $3.88 |
| 52 Week High | $10.78 | $13.50 |
Technical Indicators
Market Signals| Indicator | CEV | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 60.75 | 31.73 |
| Support Level | $10.05 | $3.92 |
| Resistance Level | $10.78 | $4.60 |
| Average True Range (ATR) | 0.14 | 0.37 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 80.82 | 13.32 |
Price Performance
Historical ComparisonAbout CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.